SD Biosensor, Inc. (KRX:137310)

Market Cap	899.54B -29.1%
Revenue (ttm)	696.13B +3.3%
Net Income	113.22B
EPS	941.16
Shares Out	119.62M
PE Ratio	7.99
Forward PE	n/a
Dividend	200.00 (2.55%)
Ex-Dividend Date	Mar 30, 2026

Volume	144,615
Average Volume	194,641
Open	7,670.00
Previous Close	7,830.00
Day's Range	7,460.00 - 7,770.00
52-Week Range	7,100.00 - 13,550.00
Beta	0.77
RSI	40.37
Earnings Date	Feb 20, 2026

About SD Biosensor

SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volume tests; and STANDARD M, a field molecular diagnosis system for infectious disease diagnosis, drug resistance, and genetic testing. It also provides ST...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1999
• Employees: 576
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 137310

Financial Performance

In 2024, SD Biosensor's revenue was 694.57 billion, an increase of 5.93% compared to the previous year's 655.68 billion. Losses were -98.41 billion, -78.96% less than in 2023.